智通财经APP讯，中国同辐(01763)发布公告，根据对本集团截至2025年12月31日止年度的未经审核综合 管理账目及现时可得数据之初步审阅，预期与2024年同期相比：收益预计约人民币69.79亿元至人民币 72.06亿元，同比减少约5%至8%;净利润预计约人民币6.11亿元至人民币6.55亿元，同比减少约25%至 30%;本公司权益股东应占年内利润预计约人民币3.02亿元至人民币3.22亿元，同比减少约20%至25%。 截至目前，公司经营运作正常，2025年度收益减少主要由于本集团的核医疗装备分部收益下降，利润减 少主要由于本公司附属公司深圳市中核海得威生物科技有限公司补缴税费及滞纳金影响。 ...

董事会认为，本集团调整前业绩由盈转亏，主要由于以下原因：期内生猪销售价格同比大幅下降，持续 于低位运行，养殖业务利润空间受到挤压，虽期内养殖成本有所改善，生鲜品牌业务有较大突破，科技 驱动成效有所显现，但整体盈利水平同比下降。 智通财经APP讯，中粮家佳康(01610)发布公告，预期本集团2025年度生物资产公允价值调整前的本公司 拥有人应占亏损约为人民币2.3亿元至人民币3.5亿元(未经审核)，去年同期调整前应占溢利约为人民币 2.59亿元。 ...

Core Viewpoint - China Traditional Chinese Medicine (0570.HK) experienced a decline of 4.57%, closing at HKD 2.09, with a trading volume of HKD 95.08 million and a market capitalization of HKD 10.5 billion. The company announced a projected loss for the fiscal year ending December 31, 2025, marking a significant shift from profit to loss, with expected losses between RMB 350 million to RMB 500 million, compared to a profit of RMB 20.77 million in the previous year. Adjusted net profit is anticipated to decrease by 45% to 55%, down from RMB 636 million in the prior year [1][1][1] Financial Performance - The company expects to report a loss for the fiscal year 2025, which would be the first loss since 2013 [1] - The adjusted net profit is projected to decline by 45% to 55%, with the previous year's figure being approximately RMB 636 million [1] Analyst Ratings - Morgan Stanley has updated its risk-reward rating for China Traditional Chinese Medicine, lowering earnings forecasts for 2026 to 2030 by 5% to 12% and reducing the target price from HKD 1.5 to HKD 1.4, maintaining a "Reduce" rating [1][1] - The firm believes there is a 70% to 80% probability that the stock price will decline over the next 30 days, primarily due to the profit warning [1][1] Market Outlook - The company faces challenges due to a shrinking market size, and it has not disclosed specific plans for market expansion through internal resources or acquisitions [1] - The market currently has low visibility regarding the company's performance in 2026, indicating further potential downside for the stock price [1]

Core Viewpoint - China Port Energy (00931) has experienced a significant decline of nearly 14%, currently trading at 0.475 HKD, with a transaction volume of 63.48 million HKD. The company anticipates a loss attributable to shareholders of approximately 65 million to 75 million HKD for the six months ending September 30, 2025, compared to a loss of about 54 million HKD for the corresponding period ending September 30, 2024. This change is primarily due to an asset disposal of around 13 million HKD during the current interim period [1]. Financial Performance - The company expects a loss of approximately 65 million to 75 million HKD for the six months ending September 30, 2025 [1] - For the corresponding period ending September 30, 2024, the anticipated loss is about 54 million HKD [1] - The asset disposal during the current interim period amounts to approximately 13 million HKD [1] Business Operations - The period from April to September is identified as the off-peak season for the company's liquefied natural gas business and the largest segment of its new energy business providing heating services in northern China [1] - The company has several new projects planned for launch in the second half of the year, which are expected to contribute positively to revenue and profitability [1] - The board expresses optimism regarding the company's transition from a loss to profit for the fiscal year ending March 31, 2026, based on current business activities and development trends [1]